Ulf Landmesser MD, FESC

Ulf Landmesser MD, FESC

Professor of Cardiology

Medical Director, Department of Cardiology

Charite University Hospital

Berlin, Germany

Related Videos

Based on ODYSSEY Outcomes, which patients in an interventional cardiology practice do you believe will benefit most from PCSK9 inhibition? Video

Based on ODYSSEY Outcomes, which patients in an interventional cardiology practice do you believe will benefit most from PCSK9 inhibition?

In your interventional cardiology practice, which markers of risk, in the patient who has undergone a PCI, do you focus on to promote consideration for using a PCSK9 inhibitor? Video

In your interventional cardiology practice, which markers of risk, in the patient who has undergone a PCI, do you focus on to promote consideration for using a PCSK9 inhibitor?

With respect to patients with HeFH and homozygous FH who are challenged with lifelong CV disease risk burden due to genetic risk, what role do you believe PCSK9 inhibitors should play, especially in younger patient populations? Video

With respect to patients with HeFH and homozygous FH who are challenged with lifelong CV disease risk burden due to genetic risk, what role do you believe PCSK9 inhibitors should play, especially in younger patient populations?

Within the context of the ESC and U.S. guidelines for LDL-C reduction, which recommend 70 mg/dL as a threshold target, how should we view the cholesterol landscape between 20 mg/dL and 70 mg/dL in light of the ODYSSEY Outcomes Trial? Video

Within the context of the ESC and U.S. guidelines for LDL-C reduction, which recommend 70 mg/dL as a threshold target, how should we view the cholesterol landscape between 20 mg/dL and 70 mg/dL in light of the ODYSSEY Outcomes Trial?

Can you discuss the ESC Guidelines for LDL-C targets and the recent AHA Guidelines designating a target threshold of 70 mg/DL? Is this low enough? What is your recommendation for PCSK9 inhibition in the high-risk ACS patient who has undergone PCI? Video

Can you discuss the ESC Guidelines for LDL-C targets and the recent AHA Guidelines designating a target threshold of 70 mg/DL? Is this low enough? What is your recommendation for PCSK9 inhibition in the high-risk ACS patient who has undergone PCI?

What has been your clinical experience with respect to the comparative toleration of statins vs. PCSK9 inhibitors? Video

What has been your clinical experience with respect to the comparative toleration of statins vs. PCSK9 inhibitors?